Last updated: November 5, 2026
JETREA, the intravitreal biologic ocriplasmin, has a commercially weak profile despite FDA approval for symptomatic vitreomacular adhesion. Its market was constrained by a narrow eligible population, variable clinical response, safety concerns, physician preference for pars plana vitrectomy, and limited repeat-use economics. Commercial revenue declined materially after launch, and JETREA ceased to be a strategic growth asset for its original developer, ThromboGenics.
The product remains an important case study in biologic ophthalmology: regulatory approval did not translate into durable market penetration, and the asset’s value shifted from a potential platform product to a limited-use specialty medicine.
What is JETREA and what condition does it treat?
JETREA is the brand name for ocriplasmin, a recombinant truncated form of human plasmin. It is administered as a single 0.125 mg intravitreal injection in 0.1 mL.
The FDA approved JETREA in October 2012 for the treatment of symptomatic vitreomacular adhesion in adults. The drug enzymatically disrupts the interaction between the vitreous body and the retina, with the objective of releasing vitreomacular traction without surgery.[1]
How does JETREA compare with surgery?
JETREA was developed as a less invasive alternative to pars plana vitrectomy. Surgery can release vitreomacular traction but carries procedural risks and requires an operating-room intervention. JETREA offered an office-based injection.
The commercial tradeoff was clinical predictability. The drug worked best in selected patients, particularly those with focal vitreomacular adhesion, small adhesion diameter, and no large full-thickness macular hole. Many patients were not appropriate candidates or did not achieve sufficient anatomical release.
| Attribute |
JETREA |
Pars plana vitrectomy |
| Administration |
Single intravitreal injection |
Surgical procedure |
| Setting |
Ophthalmology office or ambulatory setting |
Operating room or surgical center |
| Invasiveness |
Minimally invasive |
Invasive |
| Onset of treatment |
Immediate injection |
Scheduled surgery |
| Response predictability |
Variable |
Generally more predictable for appropriate anatomy |
| Repeat use |
Not routinely established or labeled |
Possible, depending on clinical need |
| Principal commercial barrier |
Narrow responder population |
Procedure cost and surgical burden |
What drove JETREA’s market performance?
JETREA underperformed its early commercial expectations because the addressable population was smaller than projected and the treatment effect was inconsistent across the broader patient population.
Narrow patient selection reduced volume
The pivotal Ocriplasmin for Treatment of Symptomatic Vitreomacular Adhesion Including Macular Hole study showed that ocriplasmin could produce nonsurgical release of vitreomacular adhesion in a subset of patients. The overall response rate was not high enough to support broad use across all symptomatic patients.[2]
Factors associated with better response included:
- Focal vitreomacular adhesion
- Smaller adhesion size
- Absence of epiretinal membrane
- Absence of a large macular hole
- Phakic lens status in certain analyses
- Limited anatomical complexity
This narrowed the commercially attractive segment. Retina specialists had to identify patients most likely to respond rather than treat the full diagnosed population.
Safety concerns weakened physician adoption
The FDA label includes warnings and precautions covering transient vision loss, photopsia, electroretinographic changes, retinal tear or detachment, increased intraocular pressure, lens subluxation, inflammation, and other ocular events.[1]
Reports of severe visual disturbances and retinal complications affected physician perception, even when events were uncommon. The risk-benefit calculation was less favorable in patients who could be managed with observation or who had a predictable surgical option.
The product had limited repeat-use economics
JETREA was labeled as a single injection. Unlike chronic retinal medicines such as anti-VEGF therapies, it did not create recurring treatment revenue from monthly or bimonthly administration. A successful injection could eliminate the need for further treatment, limiting lifetime revenue per patient.
This characteristic made market expansion dependent on new patient identification rather than treatment frequency.
What was JETREA’s financial trajectory?
JETREA’s financial trajectory followed a familiar specialty-pharmaceutical pattern: high launch expectations, early commercial expansion, rapid reassessment of the addressable market, and declining strategic importance.
ThromboGenics invested heavily in commercialization after the FDA approval and entered into a U.S. commercialization arrangement with Novartis. The partnership provided a larger commercial infrastructure but also increased the visibility of weak prescription uptake.
Financial timeline
| Period |
Commercial and financial development |
| 2012 |
FDA approval in the United States; commercial launch preparation begins |
| 2013 |
Initial launch revenues and milestone-related economics support ThromboGenics’ revenue profile |
| 2014-2015 |
Product uptake remains below early expectations; physician adoption is concentrated in selected retina practices |
| 2016 |
Commercial momentum weakens; market access, physician confidence, and patient selection remain constraints |
| 2017 |
ThromboGenics and Novartis terminate their U.S. collaboration; JETREA becomes less central to the company’s strategy |
| 2018 onward |
ThromboGenics shifts its emphasis toward ophthalmic pipeline programs, including diabetic eye disease assets |
| Late 2010s and 2020s |
JETREA no longer functions as a major growth product for the original developer |
ThromboGenics’ public filings show that the company’s economic exposure to JETREA included product revenue, licensing income, milestone payments, and royalties. Those streams were not equivalent. Milestone and collaboration revenue could temporarily improve reported results without demonstrating durable underlying product demand.[3]
Why launch revenue did not become durable revenue
The main commercial problem was not regulatory access. It was conversion from approval to routine use.
JETREA had to compete against:
- Observation for patients with manageable symptoms
- Vitrectomy for patients requiring definitive anatomical correction
- Physician uncertainty about response probability
- Patient reluctance to accept ocular adverse-event risk
- Reimbursement scrutiny for a costly biologic injection with variable benefit
A single-dose product can have attractive gross economics, but only if physicians can identify responders with sufficient accuracy. JETREA did not achieve that level of predictability in routine practice.
What is the FDA regulatory status of JETREA?
JETREA received FDA approval in 2012 under a biologics framework for symptomatic vitreomacular adhesion in adults.[1]
The approval did not cover broad treatment of retinal disease, diabetic macular edema, age-related macular degeneration, or all macular-hole cases. Its commercial label remained tied to a specific vitreomacular interface disorder.
What postmarketing issues affected JETREA?
The product label requires attention to ocular monitoring and post-injection complications. Clinical use can involve:
- Monitoring for retinal tears and retinal detachment
- Monitoring intraocular pressure
- Evaluation of reduced vision or photopsias
- Assessment for lens-related complications
- Careful patient selection based on vitreomacular anatomy
The absence of a broad chronic indication limited the product’s ability to benefit from the large retinal drug market created by anti-VEGF medicines.
What patents protect JETREA?
JETREA’s protection historically relied on patents covering ocriplasmin, recombinant production, formulations, and pharmaceutical use. The relevant patent estate was narrower than the patent portfolios supporting many large-molecule chronic therapies.
Key protection categories included:
- Composition and biologic identity of ocriplasmin.
- Recombinant manufacturing and purification processes.
- Intravitreal pharmaceutical formulations.
- Use in releasing vitreomacular adhesion.
- Treatment of selected macular-hole and vitreomacular-interface conditions.
How strong was the JETREA patent estate?
The patent estate had commercial value during the early post-approval period but did not eliminate the product’s primary weakness: limited clinical demand.
Patent protection could delay direct competition, but it could not expand the responder population or create recurring dosing. The estate also faced the normal limitations of biologic protection, including possible design-around strategies, manufacturing complexity, and the need to demonstrate a clinically acceptable product.
A current commercial assessment should separate:
- FDA Orange Book-listed patents, if any
- Biologic patent claims outside the Orange Book
- Regulatory exclusivity
- Manufacturing know-how
- Trade secrets related to recombinant production
- Market availability of competing ophthalmic interventions
Because JETREA is a biologic enzyme product rather than a conventional small-molecule tablet, manufacturing and regulatory barriers may be more important than a simple patent-expiration date.
Does JETREA face generic or biosimilar competition?
JETREA is not exposed to ordinary small-molecule generic substitution. A competing ocriplasmin product would likely require a biologic development and regulatory pathway rather than an abbreviated generic application.
What is the biosimilar risk for ocriplasmin?
Publicly visible commercial pressure has come primarily from weak demand and therapeutic alternatives, not from a large biosimilar wave.
A biosimilar or follow-on ocriplasmin product would face several barriers:
- Demonstrating analytical similarity for a recombinant proteolytic enzyme
- Establishing comparable biological activity
- Addressing ocular safety and immunogenicity
- Generating physician confidence in a narrow indication
- Building a retina-focused commercial organization
- Securing reimbursement for a product with uncertain utilization
The commercial incentive for a biosimilar entrant is limited unless the reference product has stable supply, meaningful volume, and favorable reimbursement.
What was the Novartis and ThromboGenics licensing relationship?
ThromboGenics partnered with Novartis to commercialize JETREA in the United States. The arrangement was intended to combine ThromboGenics’ product with Novartis’ ophthalmology infrastructure and commercial reach.[3]
The collaboration did not produce the expected scale. The parties later terminated the U.S. arrangement, returning greater commercial responsibility to ThromboGenics. The termination reflected weak market performance rather than a regulatory withdrawal of the product.
Why did the partnership fail to scale JETREA?
The partnership had access to commercial resources, but resources could not solve the central adoption barriers:
- Limited eligible anatomy
- Variable treatment response
- Safety concerns
- Competition from surgery
- Lack of repeat administration
- Need for highly trained retina specialists
- Restricted patient throughput
The product’s economics were therefore more dependent on clinical selection than on salesforce reach.
What patent litigation and Paragraph IV challenges affected JETREA?
JETREA has not been associated with a major, widely reported Paragraph IV litigation campaign comparable with high-revenue small-molecule blockbusters.
That outcome is commercially logical. A Paragraph IV challenge is most attractive where:
- The reference product has substantial annual sales.
- A generic can launch at high volume.
- Patent claims can be attacked at a manageable cost.
- Substitution is straightforward.
JETREA did not offer the same opportunity. A follow-on entrant would face biologic development complexity and a relatively narrow market.
No major generic-entry event appears to have driven the product’s decline. The principal erosion mechanism was commercial underperformance and loss of strategic priority.
What manufacturing barriers protect JETREA?
Ocriplasmin manufacturing involves recombinant protein expression, purification, characterization, sterile filling, and control of enzymatic activity. Product consistency is important because excessive proteolytic activity could increase ocular safety concerns, while insufficient activity could reduce efficacy.
Manufacturing know-how can therefore provide practical protection beyond formal patent rights. The main barriers include:
- Control of protein sequence and folding
- Purity and aggregate control
- Potency assays
- Sterility assurance
- Stability in an intravitreal formulation
- Container-closure compatibility
- Batch comparability
These barriers raise development costs but do not guarantee strong commercial returns. A competing product could still be unattractive if the underlying indication remains small.
How does JETREA compare with competing retinal drugs?
JETREA competes in a different clinical and economic segment from anti-VEGF products.
| Product category |
Primary use |
Dosing model |
Commercial profile |
| JETREA |
Symptomatic vitreomacular adhesion |
Generally single injection |
Narrow, procedure-substitution market |
| Anti-VEGF biologics |
Wet AMD, diabetic macular edema, retinal vein occlusion |
Repeated injections |
Large recurring-treatment market |
| Corticosteroid implants |
Selected retinal edema and inflammation |
Periodic administration |
Recurring or repeat-use market |
| Vitrectomy |
Mechanical correction of vitreoretinal pathology |
Surgical intervention |
Procedure-based economics |
Anti-VEGF products created larger and more predictable revenue pools because patients often require repeated treatment. JETREA’s one-time model reduced cumulative revenue per successfully treated patient.
What generic launch scenarios exist for JETREA?
The most plausible launch scenarios are limited:
Scenario 1: No meaningful follow-on competition
This is the most commercially likely outcome where the market remains small and physician demand is concentrated. Existing supply can serve the residual patient population.
Scenario 2: A niche follow-on biologic
A competitor could target a narrow retina-specialist market if it can offer lower cost, improved supply, or a differentiated formulation. Such a product would still need clinical credibility.
Scenario 3: Therapeutic substitution
The more important competitive threat is not a biosimilar. It is substitution by vitrectomy, observation, or future vitreoretinal therapies with better response rates and safety profiles.
What is JETREA’s current commercial value?
JETREA’s value is primarily residual and strategic rather than growth-oriented.
Potential value drivers include:
- Existing physician familiarity
- Established regulatory approval
- Manufacturing know-how
- A defined niche in vitreomacular adhesion
- Limited competition from direct biologic substitutes
- Potential licensing value in selected international markets
Value constraints include:
- Low market growth
- Limited repeat dosing
- Narrow responder population
- Ocular safety concerns
- Weak brand momentum after the Novartis relationship ended
- Competition from surgery
- High commercial cost relative to likely patient volume
For investors or licensing counterparties, JETREA should be analyzed as a mature niche biologic. Its upside depends on efficient supply, focused commercialization, and improved patient selection rather than broad market expansion.
What is the outlook for JETREA revenue?
The revenue outlook is structurally limited. A recovery would require one of four developments:
- Better clinical selection that materially increases response rates.
- New evidence supporting broader use.
- A lower-cost commercial model targeting retina specialists.
- A new formulation or delivery strategy that improves safety, convenience, or efficacy.
Absent those developments, JETREA revenue is likely to remain dependent on residual use in carefully selected patients. The product is unlikely to replicate the financial profile of chronic retinal biologics.
Key Takeaways
- JETREA is ocriplasmin, a recombinant intravitreal biologic approved by the FDA in 2012 for symptomatic vitreomacular adhesion.
- Its commercial performance was limited by variable response, a narrow eligible population, ocular safety concerns, and competition from vitrectomy.
- The single-dose treatment model reduced recurring revenue potential.
- The Novartis commercialization relationship ended after uptake failed to meet expectations.
- JETREA’s decline was driven primarily by market and clinical economics, not by a major generic or biosimilar launch.
- Patent, manufacturing, and regulatory barriers provide some protection, but they do not offset the product’s limited market size.
- JETREA is best valued as a mature niche biologic with residual commercial potential rather than as a growth asset.
FAQs
Is JETREA still FDA approved?
Yes. JETREA received FDA approval for symptomatic vitreomacular adhesion in adults. Approval status does not guarantee broad commercial availability or active promotion.
Is ocriplasmin a biologic drug?
Yes. Ocriplasmin is a recombinant protein enzyme administered by intravitreal injection.
Can JETREA be used for diabetic macular edema?
JETREA is not broadly approved for diabetic macular edema. Its FDA indication is symptomatic vitreomacular adhesion.
Why did JETREA sales decline after FDA approval?
Sales declined because the product had a limited responder population, variable clinical outcomes, safety concerns, and competition from surgery and observation.
Is there a generic version of JETREA?
There is no conventional generic equivalent. Any direct follow-on would likely require a biologic development and regulatory pathway, making biosimilar or follow-on competition more complex than ordinary generic substitution.
References
- U.S. Food and Drug Administration. (2012). JETREA (ocriplasmin) injection prescribing information. FDA.
- Stalmans, P., Benz, M. S., Gandorfer, A., Kampik, A., Girach, A., Pakola, S., & the MIVI-TRUST Study Group. (2012). Enzymatic vitreolysis with ocriplasmin for vitreomacular adhesion and macular hole. New England Journal of Medicine, 367(7), 606-615.
- ThromboGenics NV. (2012-2018). Annual reports and corporate filings. Leuven, Belgium: ThromboGenics.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
- European Medicines Agency. (2013). Jetrea: European public assessment report. EMA.